We have had the opportunity to interview
In 2015, the perfusionist team and the transplant team at GOSH in
In 2021,
Furthermore, the team at GOSH have just submitted for publication, a case report for a 9-year-old child (around 40 kg) who had an ABO-incompatible heart transplant using two Glycosorb® ABO columns placed in parallel to ensure the safe reduction in antibodies within a short time frame, demonstrating that this technology could push the boundaries of what's possible even further.
The treatment with Glycosorb® ABO has also been introduced at other heart transplant centres in
1. Robertson A, Issitt R, Crook R, Gustafsson K, Eddaoudi A, Tsang V, Burch M; A novel method for ABO-incompatible heart transplantation J Heart Lung Transplant. 2018 Apr;37(4):451-457. doi: 10.1016/j.healun.2017.05.006.Epub 2017
2. Issitt R, Crook R, Shaw M, Robertson A; The
Perfusion 2021 Jan;36(1):34-37. doi: 10.1177/0267659120926895. Epub 2020
3. Issitt R, Booth J, Crook R, Robertson A, Molyneux V, Richardson R, Cross N, Shaw M, Tsang V, Muthurangu V, Sebire NJ, Burch M, Fenton M. Intraoperative anti-A/B immunoadsorption is associated with significantly reduced blood product utilization with similar outcomes in pediatric ABO-incompatible heart transplantation. J Heart Lung Transplant. 2021 May 29:S1053-2498(21)02325-1.
For more information, please contact:
Email: johan.nilsson@glycorex.com, Tel: +46 46 286 5230
Brief information about the company
The company's focus areas are within transplantation, blood transfusion, and autoimmune diseases. The company has sales in over 25 countries, with
Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplantation by specifically reducing anti-A/B antibodies in the organ recipient's plasma. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific publications have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 6,500 transplants in over 25 countries.
The company has also developed and CE-marked a medical device variant of Glycosorb® ABO that targets a different customer segment: transfusion clinics and blood centers. The product can help increase the availability of universal blood components and has been shown to be effective for the preparation of low-titer blood plasma, whole blood, and platelet concentrate.
The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
https://news.cision.com/glycorex-transplantation/r/glycosorb--abo-is-pushing-the-boundaries-in-paediatric-blood-group-incompatible-heart-transplantatio,c3977330
(c) 2024 Cision. All rights reserved., source